These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 24032256)
21. Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease. Stanton RC Curr Diab Rep; 2013 Aug; 13(4):567-73. PubMed ID: 23653011 [TBL] [Abstract][Full Text] [Related]
22. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists]. Tesar V Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169 [TBL] [Abstract][Full Text] [Related]
23. Slowing the progression of renal disease in diabetic patients. Vivian EM; Goebig ML Ann Pharmacother; 2001 Apr; 35(4):452-63. PubMed ID: 11302410 [TBL] [Abstract][Full Text] [Related]
24. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient? de la Sierra A; Salazar J Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181 [TBL] [Abstract][Full Text] [Related]
25. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211 [TBL] [Abstract][Full Text] [Related]
26. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123 [TBL] [Abstract][Full Text] [Related]
27. Update on Diabetic Nephropathy: Core Curriculum 2018. Umanath K; Lewis JB Am J Kidney Dis; 2018 Jun; 71(6):884-895. PubMed ID: 29398179 [TBL] [Abstract][Full Text] [Related]
28. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy]. Fronczyk A; Majkowska L Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038 [TBL] [Abstract][Full Text] [Related]
29. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D? Alsaeed A Saudi Med J; 2021 Jan; 42(1):115. PubMed ID: 33399181 [TBL] [Abstract][Full Text] [Related]
30. ACEI and ARB Lower the Incidence of End-Stage Renal Disease among Patients with Diabetic Nephropathy: A Meta-analysis. Deng X; Li D; Tang Q; Chen Y Comput Math Methods Med; 2022; 2022():6962654. PubMed ID: 35685896 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease. Jiang S; Fang J; Yu T; Li W Eur J Intern Med; 2021 Mar; 85():127-129. PubMed ID: 33250340 [No Abstract] [Full Text] [Related]
32. End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes. Shani M; Vinker S; Feldman L J Clin Hypertens (Greenwich); 2017 Jun; 19(6):627-631. PubMed ID: 28177196 [TBL] [Abstract][Full Text] [Related]
33. [A clinical evaluation on the combination therapy with ACE-I and ARB, and with ARB and CCB in patients with progressive chronic renal diseases]. Kuriyama S Nihon Rinsho; 2002 Oct; 60(10):2014-9. PubMed ID: 12397700 [TBL] [Abstract][Full Text] [Related]
35. ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner? Lewis EJ; Lewis JB J Am Soc Nephrol; 2004 May; 15(5):1358-60. PubMed ID: 15100380 [No Abstract] [Full Text] [Related]
36. Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment. de Goeij MC; Liem M; de Jager DJ; Voormolen N; Sijpkens YW; Rotmans JI; Boeschoten EW; Dekker FW; Grootendorst DC; Halbesma N; Nephron Clin Pract; 2012; 121(1-2):c73-82. PubMed ID: 23128440 [TBL] [Abstract][Full Text] [Related]
38. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study. Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957 [TBL] [Abstract][Full Text] [Related]
39. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Rosner MH; Okusa MD Arch Intern Med; 2003 May; 163(9):1025-9. PubMed ID: 12742799 [TBL] [Abstract][Full Text] [Related]
40. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]